FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * <u>Trautwein Leonardo Mouta</u>					KN	2. Issuer Name and Ticker or Trading Symbol KNOW LABS, INC. [ KNWN ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner					
(Last) 500 UNION S	(First)	t) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 03/15/2023								X	X Officer (give title below)  Chief Marketing Off				specify	
SUITE 810					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person					
(Street) SEATTLE	WA	WA 98101													Form filed by More than One Reporting Person					
(City)	(State	) (Z	Zip)																	
		Т	able I - Noi			_			<del></del>	Disp		•								
					2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5. Amount Securities Beneficiall Following	ly Owned or I Reported (Ins		nership : Direct (D) direct (I) : 4)	7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	t (A) or (D) Pri		Price	Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Common Stoc	k			03/1	15/2023				P		6,00	6,000 A \$		\$0.8399	19,9	19,980		D		
			Table II - I (						ired, Di option						ed					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Code (Ins			Derivative E		6. Date Exercisat Expiration Date (Month/Day/Year)			7. Title and Amount Securities Underlyi Derivative Security 3 and 4)		erlying	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				C	ode	v	(A)	(D)	Date Exercisab		xpiration ate	Title		Amount or Number of Shares		Transaction(s (Instr. 4)				
Option to Purchase Common Stock	\$2.04								(1)	0:	2/04/2026		nmon ock	200,000	200,		00 D			
Option to Purchase Common Stock	\$2.35								(2)	0:	2/09/2026		nmon ock	100,000		100,0	00	D		
Option to Purchase Common Stock	\$2.09								(3)	13	2/16/2026		nmon ock	100,000	100		00	D		
Option to Purchase Common Stock	\$1.48								(3)	0:	5/20/2027		nmon ock	600,000		600,00	00	D		

## Explanation of Responses:

- 1. Options vest quarterly over four years. No vesting during first 6 months.
- 2. Options vest upon FDA approval
- 3. Options vest quarterly over four years.

/s/ Leonardo M. Trautwein

03/15/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.